International pharmaceutical firm Angelini Pharma has launched a new crowdsourcing campaign that aims to capture innovative new ways of target identification in epilepsy, particularly approaches that address the issue of drug-resistant phenotypes.
The campaign is the first of a new Angelini Pharma partnership with innovation scale-up Wazoku and is being dubbed an ‘open innovation challenge’ and focuses on identifying innovative digital approaches.
